Abstract:Background: Routine clinical surveillance involves serial radiographic imaging following radical surgery in localized non-small cell lung cancer (NSCLC). However, such surveillance can detect only macroscopic disease recurrence and is frequently inconclusive. We investigated if detection of ctDNA before and after resection of NSCLC identifies the patients with risk of relapse, and furthermore, informs about response to management.Methods: We recruited a total of 77 NSCLC patients. A high-throughput 127 target-gene capture technology and a high-sensitivity circulating single-molecule amplification and resequencing technology (cSMART) assay were used to detect the somatic mutations in the tumor tissues as well as the plasma of NSCLC patients before and after surgery to monitor for minimal residual disease (MRD). Kaplan-Meier and Cox regression analysis were performed to evaluate the relapse-free survival (RFS) and overall survival (OS) of patients with predictor variables.Results: Patients with a higher stage (III/IV) and preoperative ctDNA-positive status demonstrated a significant 2.8-3.4-fold risk and 3.8-4.0-fold risk for recurrence and death, respectively. Preoperative ctDNA-positive patients associated with a lower RFS (HR = 3.812, p = 0.0005) and OS (HR = 5.004, p = 0.0009). Postoperative ctDNA-positive patients also associated with a lower RFS (HR = 3.076, p = 0.0015) and OS (HR = 3.195, p = 0.0053). Disease recurrence occurred among 63.3% (19/30) of postoperative ctDNA-positive patients. Most of these patients 89.5% (17/19) had detectable ctDNA within 2 weeks after surgery and was identified in advance of radiographic findings by a median of 12.6 months.Conclusion: Advanced stage and preoperative ctDNA-positive are strong predictors of RFS and OS in localized NSCLC patients undergoing complete resection. Postoperative detection of ctDNA increases chance to detect early relapse, thus can fulfill an important role in stratifying patients for immediate further treatment with adjuvant and neoadjuvant therapy.

Tumor-suppressive Activity of Strail on Circulating CD44+ Cells in Patients with Non-Small Cell Lung Cancer

A Radiomic Approach to Access Tumor Immune Status by CD8<SUP>+</SUP>TRMs on Surgically Resected Non-Small-Cell Lung Cancer

Prognostic significance of TRAIL signalling molecules in cervical squamous cell carcinoma

Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer

Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail)-Induced Apoptosis in NSCLC Cells

Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo.

Tumor necrosis factor-related apoptosis-inducing ligand modulates angiogenesis and apoptosis to inhibit non-small cell lung carcinoma tumor growth in mice

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies

Circulating Tumor cells and multiple indicators combined to identify the risk of poorer prognosis in patients with resected non-small cell lung cancer

TRAIL predisposes non-small cell lung cancer to ferroptosis by regulating ASK-1/JNK1 pathway

The Clinical Value of Plasma Soluble Tumour Necrosis Factor Related Apoptosis Inducing Ligand Level in Patients with Systemic Lupus Erythematosus

The Prognostic Roles of Circulating ALDH1(+) Tumor Cell in the Patients with Non-Small Cell Lung Cancer

The Diagnostic Value of Circulating Stanniocalcin-1 Mrna in Non-Small Cell Lung Cancer

Plasma Thioredoxin Reductase Activity, a Diagnostic Biomarker, is Up-Regulated in Resectable Non-Small Cell Lung Cancers

The Roles and Mechanisms of TRAT1 in the Progression of Non-Small Cell Lung Cancer

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer

Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.

Expression and significance of CD4+CD25high regulatory T cells in patients with non-small-cell lung cancer

TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas

Effect of sodium butyrate combined with TRAIL on biological behaviors of lung cancer stem cells